Literature DB >> 9917503

Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.

T Nakagawa1, T Seki, T Shiro, M Wakabayashi, M Imamura, T Itoh, T Tamai, A Nishimura, N Yamashiki, K Matsuzaki, N Sakaida, K Inoue, A Okamura.   

Abstract

Protein induced vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) have been considered useful serum markers of hepatocellular carcinoma (HCC). In this study, we examined the clinicopathologic significance of these tumour markers in patients with HCCs by measuring their serum levels and performing immunohistochemistry. We studied 349 Japanese patients with HCCs. Their serum PIVKA-II and AFP levels were determined by enzyme immunoassay before treatment. We examined the correlations between serum PIVKA-II and AFP levels and tumour size, presence of satellite nodules, histologic HCC grade, and concomitant liver diseases and subjected tumour tissues to immunohistochemical staining to detect PIVKA-II and AFP expression. The serum PIVKA-II levels of patients with poorly differentiated HCCs were significantly higher than those of patients with well and moderately differentiated HCCs (p<0.05) and they were higher in HCC patients with than without satellite nodules. The serum AFP levels were influenced significantly by concomitant liver diseases, but not by the other factors. Immunohistochemical staining revealed the PIVKA-II expression levels of poorly differentiated HCCs were higher than those of well and moderately differentiated HCCs (p<0.05). Some HCC cells were PIVKA-II-positive, others were AFP-positive, and some expressed both. The serum PIVKA-II concentration was a better indicator of HCC than AFP, as it was not influenced by concomitant liver diseases. The presence of PIVKA-II in serum correlated with the presence of satellite nodules and the histologic HCC grade, a result concordant with the immunohistochemical findings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9917503     DOI: 10.3892/ijo.14.2.281

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

Review 1.  Serum markers of hepatocellular carcinoma.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Massimiliano Berretta; Alessandro Cappellani; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2010-03-26       Impact factor: 3.199

2.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

3.  Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma.

Authors:  Min Dong; Zhan-Hong Chen; Xing Li; Xiao-Yun Li; Jing-Yun Wen; Qu Lin; Xiao-Kun Ma; Li Wei; Jie Chen; Dan-Yun Ruan; Ze-Xiao Lin; Tian-Tian Wang; Dong-Hao Wu; Xiang-Yuan Wu
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

4.  Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy.

Authors:  Atsushi Nanashima; Yorihisa Sumida; Takafumi Abo; Hisakazu Shindou; Hidetoshi Fukuoka; Hiroaki Takeshita; Shigekazu Hidaka; Kenji Tanaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu; Katsuhisa Omagari; Mariko Mine
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

5.  Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis.

Authors:  A Nanashima; Y Sumida; S Tobinaga; K Shibata; H Shindo; M Obatake; S Shibasaki; N Ide; Takeshi Nagayasu
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 6.  Present and future possibilities for early diagnosis of hepatocellular carcinoma.

Authors:  Piotr Stefaniuk; Janusz Cianciara; Alicja Wiercinska-Drapalo
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

7.  Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP).

Authors:  Kazuhiro Matsueda; Hiroshi Yamamoto; Yasuo Yoshida; Kenji Notohara
Journal:  J Gastroenterol       Date:  2006-11-09       Impact factor: 6.772

8.  Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma.

Authors:  Naota Taura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Eisuke Ozawa; Takuya Tsutsumi; Shotaro Tsuruta; Yuji Kato; Takashi Goto; Noboru Kinoshita; Masanori Fukushima; Hiroyuki Kato; Kazuyuki Ohata; Kazuo Ohba; Junichi Masuda; Keisuke Hamasaki; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2013-09-06

9.  Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma.

Authors:  N Toshikuni; K Nouso; T Higashi; H Nakatsukasa; T Onishi; T Kaneyoshi; Y Kobayashi; K Kariyama; K Yamamoto; T Tsuji
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

10.  Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.

Authors:  Jun Li; Zhang-Jun Cheng; Yang Liu; Zhen-Lin Yan; Kui Wang; Dong Wu; Xu-Ying Wan; Yong Xia; Wan Yee Lau; Meng-Chao Wu; Feng Shen
Journal:  Oncotarget       Date:  2015-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.